Dataset Information

Clinical study to examine the effectiveness of Juzentaihoto in postoperative recovery for colorectal cancer patients - A research investigating the role of cell-mediated immunity in recovery

ABSTRACT: Interventions: Juzentaihoto is administered orally 7.5g/day in 2-3 dosages, before or between meals Total duration of test: 24 weeks starting from one week after surgery Juzentaihoto is not administered. Primary outcome(s): 1.ECOG’s Performance Status (ECOG=Eastern Cooperative Oncology Group) 2.Weight 3.QOL-ACD (The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs) 4.Hematological test (RBC, Hb, Ht, WBC, differential leukocyte count, PLT) 5.Serum albumin 6.Cell-mediated immunity (HLA-DR/CD3, CD11b/CD8, NK-cell activity) 7.Blood cytokine (IL-6, IL-10, IL-12, IL-18, TGF-beta, IFN-gamma) 8.Carcinoembryonic antigen (CEA) 9.Recurrence of cancer 10.Metastasis of cancer 11.Duration of anticancer drug therapy Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2616728 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:The inflammatory response after spinal cord injury (SCI) is an important contributor to secondary damage. Infiltrating macrophages can acquire a spectrum of activation states, however, the microenvironment at the SCI site favors macrophage polarization into a pro-inflammatory phenotype, which is one of the reasons why macrophage transplantation has failed. In this study, we investigated the therapeutic potential of the macrophage secretome for SCI recovery. We investigated the effect of the secretome in vitro using peripheral and CNS-derived neurons and human neural stem cells. Moreover, we perform a pre-clinical trial using a SCI compression mice model and analyzed the recovery of motor, sensory and autonomic functions. Instead of transplanting the cells, we injected the paracrine factors and extracellular vesicles that they secrete, avoiding the loss of the phenotype of the transplanted cells due to local environmental cues. We demonstrated that different macrophage phenotypes have a distinct effect on neuronal growth and survival, namely, the alternative activation with IL-10 and TGF-β1 (M(IL-10+TGF-β1)) promotes significant axonal regeneration. We also observed that systemic injection of soluble factors and extracellular vesicles derived from M(IL-10+TGF-β1) macrophages promotes significant functional recovery after compressive SCI and leads to higher survival of spinal cord neurons. Additionally, the M(IL-10+TGF-β1) secretome supported the recovery of bladder function and decreased microglial activation, astrogliosis and fibrotic scar in the spinal cord. Proteomic analysis of the M(IL-10+TGF-β1)-derived secretome identified clusters of proteins involved in axon extension, dendritic spine maintenance, cell polarity establishment, and regulation of astrocytic activation. Overall, our results demonstrated that macrophages-derived soluble factors and extracellular vesicles might be a promising therapy for SCI with possible clinical applications.

Dataset Information

Clinical study to examine the effectiveness of Juzentaihoto in postoperative recovery for colorectal cancer patients - A research investigating the role of cell-mediated immunity in recovery

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure